In alignment with targeting CD19, CLN-978, a CD3 × CD19 × serum albumin fbAb, is being investigated for a clinical trial in hematological malignancy [194] and SLE (NCT06613360), which has shown promising results as announced by the company and is being investigated for phase 1b trial for SLE [195]. This evidence concerns the gene ALB and systemic lupus erythematosus.